Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PIK3C3 | Q8NEB9 | 3/20 | 0.38 |
| ▸ | HTR1F | P30939 | 2/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
| ▸ | FASN | P49327 | 4/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.35 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4076035 | 0.99 | L3MBTL1 (0.39) | L3MBTL1PIK3C3HTR1FCRBNHTR1A | |
| Hydrochloric Acid SCHEMBL4068376 | 0.89 | L3MBTL1 (0.39) | L3MBTL1PIK3C3HTR1FCRBNHTR1A | |
| SCHEMBL16836095 | 0.78 | AVPR1A (0.47) | FASNKCNH2MCHR1AVPR1A | |
| SCHEMBL4071328 | 0.76 | AVPR1A (0.44) | KCNH2MCHR1AVPR1A | |
| SCHEMBL1534968 | 0.75 | MCHR1 (0.47) | KCNH2MCHR1AVPR1A | |
| Hydrochloric Acid SCHEMBL1002825 | 0.74 | MCHR1 (0.46) | KCNH2MCHR1AVPR1A | |
| Hydrochloric Acid SCHEMBL4074084 | 0.74 | NOS3 (0.34) | KCNH2MCHR1AVPR1A | |
| SCHEMBL16836255 | 0.70 | AVPR1A (0.47) | FASNAVPR1A | |
| SCHEMBL30591620 | 0.68 | KDM4E (0.43) | FASN | |
| SCHEMBL13519214 | 0.67 | KCNH2 (0.37) | KCNH2MCHR1AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247560-A1 | Diaryl ketimine derivative | BANYU PHARMACEUTICAL CO., LTD. | 2009-10-01 | — | — | US | disclosed |
| US-20090247560-A1 | Diaryl ketimine derivative | BANYU PHARMACEUTICAL CO., LTD. | 2009-10-01 | — | — | US | disclosed |
| EP-2072519-A1 | DIARYL KETIMINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247560-A1 | Diaryl ketimine derivative | NR0B2, NR2C2, NR3C2 | L3MBTL1 1199/4885PIK3C3 4625/4885HTR1F 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.